BTIG Research Reiterates "Buy" Rating for BioAge Labs (NASDAQ:BIOA)

Key Points

• BTIG Research reiterated a “Buy” rating on BioAge Labs with a $40 price target, implying 324.18% upside from the prior close.
• Analyst sentiment is broadly positive: six analysts rate the stock Buy and one rates it Sell, producing a “Moderate Buy” consensus and an average target of $36.57.
• BioAge shares fell 1.7% to $9.43, while the company reported a quarterly loss of $0.58 per share—better than the expected $0.65 loss—and revenue of $2.45 million.

BioAge Labs (NASDAQ:BIOA - Get Free Report)'s stock had its "buy" rating reissued by analysts at BTIG Research in a research report issued on Tuesday, Benzinga reports. They presently have a $40.00 price objective on the stock. BTIG Research's price target indicates a potential upside of 324.18% from the company's previous close.

BIOA has been the topic of a number of other research reports. Jefferies Financial Group set a $21.00 target price on BioAge Labs in a research report on Friday, July 31st. Roth Capital reissued a "buy" rating and issued a $25.00 price objective on shares of BioAge Labs in a report on Friday, July 31st. Needham & Company LLC lowered their target price on shares of BioAge Labs from $50.00 to $35.00 and set a "buy" rating on the stock in a report on Friday, July 31st. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of BioAge Labs in a research report on Tuesday, July 21st. Finally, Wall Street Zen downgraded shares of BioAge Labs from a "sell" rating to a "strong sell" rating in a research note on Saturday. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $36.57.

BioAge Labs Trading Down 1.7%

Shares of NASDAQ BIOA traded down $0.16 during midday trading on Tuesday, reaching $9.43. The company's stock had a trading volume of 87,498 shares, compared to its average volume of 693,825. The stock has a 50 day simple moving average of $16.19 and a 200-day simple moving average of $17.74. The stock has a market capitalization of $432.81 million, a price-to-earnings ratio of -3.97 and a beta of 0.94. BioAge Labs has a fifty-two week low of $4.68 and a fifty-two week high of $25.95.

BioAge Labs (NASDAQ:BIOA - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.07. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. The business had revenue of $2.45 million during the quarter. As a group, equities analysts anticipate that BioAge Labs will post -2.45 EPS for the current year.

Institutional Investors Weigh In On BioAge Labs

Hedge funds have recently bought and sold shares of the stock. Corient Private Wealth LP boosted its holdings in shares of BioAge Labs by 76.7% during the second quarter. Corient Private Wealth LP now owns 40,258 shares of the company's stock worth $987,000 after acquiring an additional 17,476 shares during the period. California State Teachers Retirement System boosted its stake in BioAge Labs by 531.8% in the 2nd quarter. California State Teachers Retirement System now owns 10,368 shares of the company's stock valued at $254,000 after purchasing an additional 8,727 shares during the period. Yiheng Capital Management L.P. bought a new stake in BioAge Labs in the 2nd quarter valued at $4,180,000. Wellington Management Group LLP grew its holdings in BioAge Labs by 39.9% in the 2nd quarter. Wellington Management Group LLP now owns 94,656 shares of the company's stock valued at $2,320,000 after buying an additional 26,975 shares in the last quarter. Finally, Stonepine Capital Management LLC bought a new position in BioAge Labs during the 2nd quarter worth $490,200.

About BioAge Labs

BioAge Labs NASDAQ: BIOA is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.